|
DRUG INTERACTIONS
Drug Interactions
Formal interaction studies of TNKase with other drugs
have not been performed. Patients studied in clinical trials of
TNKase were routinely treated with heparin and aspirin.
Anticoagulants (such as heparin and vitamin K antagonists) and
drugs that alter platelet function (such as acetylsalicylic
acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the
risk of bleeding if administered prior to, during, or after
TNKase therapy.
|
|
CONTRAINDICATIONS
TNKase therapy in patients with acute
myocardial infarction is contraindicated in the following situations
because of an increased risk of bleeding (see WARNINGS):
-
Active internal bleeding
-
History of cerebrovascular
accident
-
Intracranial or intraspinal surgery or
trauma within 2 months
-
Intracranial neoplasm, arteriovenous
malformation, or aneurysm
-
Known bleeding diathesis
-
Severe uncontrolled hypertension
|
REFERENCES
- ASSENT-2 Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet1999;354:716-22.
- Cannon CP, Gibson CM, McCabe CH, Adgey AAJ, Schweiger MJ, Sequeira RF, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction. Results of the TIMI 10B trial. Circulation1998;98:2805–14.
- Van de Werf F, Cannon CP, Luyten A, Houbracken K, McCabe CH, Berioli S, et al. Safety assessment of a single bolus administration of TNK tissue- plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. Am Heart J1999;137:786–91.
TNKase® [Tenecteplase]
|
Manufactured by:
Genentech, Inc.
A Member of the Roche Group 1 DNA Way South San Francisco, CA 94080-4990 |
4851700 Initial US Approval June 2000 Revision Date May 2011
TNKase is a registered Trademark of Genentech, Inc.
©2011 Genentech, Inc. |
|
|
|
-- advertisement --
|